MX2022014416A - Precursores del inhibidor de la pde4 bioactivados para la microbiota intestinal. - Google Patents

Precursores del inhibidor de la pde4 bioactivados para la microbiota intestinal.

Info

Publication number
MX2022014416A
MX2022014416A MX2022014416A MX2022014416A MX2022014416A MX 2022014416 A MX2022014416 A MX 2022014416A MX 2022014416 A MX2022014416 A MX 2022014416A MX 2022014416 A MX2022014416 A MX 2022014416A MX 2022014416 A MX2022014416 A MX 2022014416A
Authority
MX
Mexico
Prior art keywords
bioactivated
pde4 inhibitor
intestinal microbiota
methods
inhibitor precursors
Prior art date
Application number
MX2022014416A
Other languages
English (en)
Spanish (es)
Inventor
Bernard Côté
Original Assignee
Giiant Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giiant Pharma Inc filed Critical Giiant Pharma Inc
Publication of MX2022014416A publication Critical patent/MX2022014416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022014416A 2020-05-28 2021-05-28 Precursores del inhibidor de la pde4 bioactivados para la microbiota intestinal. MX2022014416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031023P 2020-05-28 2020-05-28
PCT/CA2021/050725 WO2021237364A1 (en) 2020-05-28 2021-05-28 Gut microbiota bioactivated pde4 inhibitor precursors

Publications (1)

Publication Number Publication Date
MX2022014416A true MX2022014416A (es) 2023-02-22

Family

ID=78745382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014416A MX2022014416A (es) 2020-05-28 2021-05-28 Precursores del inhibidor de la pde4 bioactivados para la microbiota intestinal.

Country Status (9)

Country Link
US (1) US20230250123A1 (https=)
EP (1) EP4157853B1 (https=)
JP (1) JP7762168B2 (https=)
KR (1) KR20230029682A (https=)
CN (1) CN116056713B (https=)
AU (1) AU2021280418A1 (https=)
ES (1) ES2989065T3 (https=)
MX (1) MX2022014416A (https=)
WO (1) WO2021237364A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2007142929A2 (en) * 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors

Also Published As

Publication number Publication date
KR20230029682A (ko) 2023-03-03
JP7762168B2 (ja) 2025-10-29
JP2023528397A (ja) 2023-07-04
EP4157853B1 (en) 2024-07-31
CN116056713B (zh) 2025-09-09
US20230250123A1 (en) 2023-08-10
CN116056713A (zh) 2023-05-02
ES2989065T3 (es) 2024-11-25
WO2021237364A1 (en) 2021-12-02
AU2021280418A1 (en) 2023-02-02
CA3174137A1 (en) 2021-12-02
EP4157853A1 (en) 2023-04-05
EP4157853A4 (en) 2023-12-13
EP4157853C0 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
SA521430920B1 (ar) P2x3 مشتقات أمينو كينازولين كمثبطات
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
JOP20220284A1 (ar) إيميدازوبيريدازين في صورة مُعدِلات il-17
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
PH12018500765A1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
MY194850A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
MY194313A (en) Substituted chromanes and method of use
MX2019000785A (es) Compuestos diazaheterobiciclicos sustituidos y su uso.
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
JP2018513107A5 (https=)
TW200518758A (en) HIV replication inhibiting purine derivatives
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
GB0324654D0 (en) Medicinal compounds
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
BR112012017071A2 (pt) produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
MX2009003100A (es) Inhibidores de fosfodiesterasa tipo iv.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112017013253A2 (pt) comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes
MX2022014416A (es) Precursores del inhibidor de la pde4 bioactivados para la microbiota intestinal.
MX2010004727A (es) Nuevos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo y composicion farmaceutica de los mismos para el tratamiento de la eyaculacion precoz.
ZA202404599B (en) Heteroalicyclic derivatives and their use in the treatment of cns disorders
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
MX385650B (es) Derivado de bisamida de acido dicarboxilico como agente que estimula regeneracion de tejidos y recuperacion de funcion tisular disminuida.